| mRNA |
doxorubicin:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.0024 |
0.9 |
| mRNA |
GSK525762A |
CTRPv2 |
pan-cancer |
AAC |
-0.0021 |
0.9 |
| mRNA |
WAY-362450 |
CTRPv2 |
pan-cancer |
AAC |
-0.0026 |
0.9 |
| mRNA |
Docetaxel |
CTRPv2 |
pan-cancer |
AAC |
0.0033 |
0.9 |
| mRNA |
BRD-K61166597 |
CTRPv2 |
pan-cancer |
AAC |
0.0022 |
0.9 |
| mRNA |
sirolimus:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.0022 |
0.9 |
| mRNA |
UNC0638:navitoclax (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.0024 |
0.9 |
| mRNA |
methylstat |
CTRPv2 |
pan-cancer |
AAC |
0.0026 |
0.9 |
| mRNA |
BRD-K13999467 |
CTRPv2 |
pan-cancer |
AAC |
-0.0023 |
0.9 |
| mRNA |
BRD-K02251932 |
CTRPv2 |
pan-cancer |
AAC |
-0.0023 |
1 |